Climate change and global warming driven by air pollution and carbon emissions are contributing to worsening respiratory health and increasing numbers of asthma-related emergencies and deaths.

In January 2023, the FDA approved this pressurized metered-dose inhaler with a fixed-dose combination of albuterol and budesonide for use as rescue medication among patients with asthma aged 18 ...

It is a pressurized metered-dose inhaler that combines albuterol and budesonide. The FDA approved the inhaler in January 2023 for use as needed to manage or prevent asthma symptoms and reduce the ...

In the on-treatment efficacy population, the combination rescue inhaler nearly halved severe exacerbations, with a rate of 5.1% versus 9.1% in the control group receiving albuterol-only rescue ...

A 2016 study from the University of Arizona found that the overuse of albuterol ... collaboration with inhaler manufacturer Chiesi, examined 2,614 pressurised metered-dose inhalers (pMDIs ...

Take the market for albuterol inhalers ... 2022 the programs had a combined gross spending of $5.3 billion on metered dose inhalers produced by AstraZeneca and GSK, according to an E&E News ...

In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose inhaler containing albuterol and budesonide—significantly reduced the risk of severe exacerbation when used as an as-needed ...

DevPro Biopharma and Bespak have announced the completion of early feasibility studies on DP007, a new formulation of albuterol in a pressurized metered dose inhaler (pMDI) which shows comparable ...

DevPro Biopharma and Bespak have announced the completion of early feasibility studies on DP007, a new formulation of albuterol in a pressurized metered dose inhaler (pMDI) which shows comparable ...